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Dacomitinib is a second-generation, irreversible, covalent pan-HER tyrosine-kinase inhib-
itor (TKI). It showed potent EGFR signaling inhibition in experimental models, including 
first-generation TKI-resistant non-small cell lung cancer (NSCLC) cell lines. This preclin-
ical efficacy did not translate into clinically meaningful treatment benefits for advanced, 
pretreated, molecularly unselected NSCLC patients enrolled in two parallel phase III trials. 
Dacomitinib and erlotinib showed overlapping efficacy data in chemotherapy-pretreated 
EGFR wild-type (WT) patients in the ARCHER 1009 trial. Similarly, it failed to demon-
strate any survival benefits as compared to placebo in EGFR WT subsets progressing 
on chemotherapy and at least one previous first-generation TKI (erlotinib or gefitinib) in 
the BR.26 trial. In the case of EGFR-mutant NSCLCs, a pooled analysis of the ARCHER 
1009 and ARCHER 1028 trials comparing the efficacy of dacomitinib vs. erlotinib in 
chemotherapy-pretreated, EGFR TKI-naïve patients showed a trend to a longer progres-
sion-free survival (PFS) and overall survival in favor of dacomitinib that did not reach 
statistical significance, with a higher rate of treatment related adverse events (mainly skin 
rash, paronychia, and gastrointestinal toxicities). On the other hand, the clinical activity 
in patients with EGFR-mutant NSCLCs with acquired TKI resistance that were included 
in phase II/III trials was equally poor (response rate <10%; PFS 3–4 months). Therefore, 
with the results of the ARCHER 1050 trial (NCT01774721) still pending, the current clinical 
development of dacomitinib is largely focused on EGFR-mutant, TKI-naïve patients. Here, 
we review the most relevant clinical data of dacomitinib in advanced NSCLC. We discuss 
the potential role of dacomitinib in pretreated EGFR WT and EGFR-mutant (TKI-naïve 
and TKI-resistant) patients. Finally, we briefly comment the available clinical data of daco-
mitinib in HER2-mutant NSCLC patients.
Keywords: non-small cell lung cancer, second-line treatment, eGFR mutations, second-generation eGFR tyrosine-
kinase inhibitors, dacomitinib, acquired resistance
iNTRODUCTiON
Second-line treatment options for advanced non-small cell lung cancer (NSCLC) patients have sub-
stantially expanded in the past few years. Docetaxel- or pemetrexed-based chemotherapy and erlotinib 
were the only three drugs approved in our setting until year 2014, achieving an approximate 8–10% of 
response rates (RRs), median 4 months of progression-free survival (PFS) and 8–10 months of overall 
survival (OS) (1). Recently, antiangiogenics [ramucirumab (2), nintedanib (3), and bevacizumab (4)] 
and particularly PD-1/PD-L1 inhibitors [nivolumab (5, 6), pembrolizumab (7), and atezolizumab (8)] 
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have shown to prolong survival in pretreated patients, transforming 
the standardization of second-line NSCLC treatment.
In the absence of significant differences in terms of efficacy, 
the choice between pemetrexed- or docetaxel-based second-line 
chemotherapy is largely driven by three factors: histology, as pem-
etrexed is restricted to non-squamous tumors, type of platinum 
doublet used during first-line treatment, with pemetrexed being 
increasingly incorporated into the first-line or maintenance treat-
ments, and differences in toxicity profiles. On the other hand, 
when deciding between chemotherapy and erlotinib, apart from 
clinical factors, EGFR mutation status is the main biomarker that 
determines treatment selection.
The IPASS trial definitely demonstrated that the clinical activ-
ity of EGFR tyrosine-kinase inhibitors (TKIs) in treatment-naïve 
patients was restricted to those with EGFR-mutant tumors 
(EGFR-sensitizing mutations). As the clinical activity of EGFR 
TKIs in TKI-naïve, EGFR-mutant tumors is comparable between 
treatment-naïve or platinum-pretreated patients (9), first- or 
second-generation EGFR TKIs are the preferred treatment options 
in patients with EGFR-mutant tumors. On the contrary, in patients 
with EGFR wild-type (WT) cancers, RRs and survival were signifi-
cantly lower with gefitinib- compared to platinum-based chemo-
therapy in the IPASS study (10). However, whether this was also true 
in the second-line setting, a clinical context in which the efficacy 
of docetaxel- or pemetrexed-based chemotherapy hardly reaches 
10% of RRs, has been a matter of extensive debate in the past few 
years. Some molecularly unselected randomized trials, initiated 
at a time where no definitive predictive biomarkers for the benefit 
or EGFR TKIs were discovered yet, initially suggested similar effi-
cacy outcomes between erlotinib and second-line chemotherapy 
(11–13). More recent data, including molecularly selected or 
molecularly stratified randomized trials and large meta-analysis, 
have confirmed that second-line chemotherapy is superior to EGFR 
TKIs in patients with EGFR WT tumors, at least in terms of RRs 
and PFS. OS differences did not reach statistical significance (14–16).
In this therapeutic scenario, and considering that EGFR pathway 
activation might hypothetically contribute to cancer progression 
even in tumors with no EGFR activating mutations (17), to investi-
gate if a more potent pan-HER inhibition with dacomitinib would 
add any clinical benefit seemed a rational approach, either from a 
biological or a clinical perspective. In addition, as the majority of 
patients with EGFR-mutant tumors treated with first-generation 
EGFR TKIs develop acquired resistance by ERBB-dependent 
mechanisms (18), and considering that dacomitinib showed 
activity in gefitinib-resistant preclinical lung cancer models (19), it 
was also rational to test its clinical activity in patients with EGFR-
mutant, TKI-resistant cancers. Herein, we will succinctly discuss 
the potential role of second-line dacomitinib in EGFR WT and 
EGFR-mutant NSCLC.
DACOMiTiNiB: PReCLiNiCAL AND eARLY 
CLiNiCAL DATA iN NSCLC
Dacomitinib is a second-generation, irreversible, covalent-
binding pan-HER TKI. As compared to first-generation EGFR 
TKIs, it has comparable inhibitory activity against the WT 
EGFR kinase in vitro. However, dacomitinib is more potent than 
gefitinib against cell lines harboring common EGFR-sensitizing 
mutations (del19, L858R). Moreover, it has inhibitory activity 
against gefitinib-resistant exon 20 insertions and acquired resist-
ance exon 20 T790M mutations in preclinical lung cancer models. 
Unlike gefitinib or other first-generation TKIs, dacomitinib, as 
a pan-ERBB inhibitor, also inhibits the activity of both WT and 
mutant HER2 kinase (19, 20).
Three phase I trials, conducted both in Western and Asian 
patients, established that the maximum tolerated dose of dacomi-
tinib was 45 mg daily, and this dose level was selected for further 
clinical evaluation. The most frequent dose-limiting drug-related 
adverse events were skin and gastrointestinal toxicities (21–23). 
The three trials consistently demonstrated that plasma concen-
trations and other pharmacokinetic parameters proportionally 
increased with increasing doses of oral dacomitinib (21–23), with 
no apparent food effect (21). Dacomitinib’s half-life was estimated 
at 59–85 h in the phase I trial conducted in the United States (21). A 
modest preliminary clinical activity was observed in small cohorts 
of NSCLC patients previously treated with first-generation EGFR 
TKIs and/or chemotherapy. No objective responses were seen 
in EGFR TKI-resistant patients whose tumors harbored EGFR 
T790M mutations (21–23).
DACOMiTiNiB FOR PReTReATeD  
NSCLC PATieNTS
Clinical Data in EGFR wT or NSCLCs 
Unselected by EGFR Status
The clinical activity of dacomitinib in pretreated NSCLC patients 
has been evaluated in four clinical trials (24–27). They are mostly 
molecularly unselected trials and, consequently, the vast majority 
of the patients included had EGFR WT tumors. An overview of 
the four clinical trials and the efficacy data in the overall study 
population are summarized in Table 1.
Two phase II trials initially suggested some degree of clinical 
activity in pretreated NSCLC patients. The ARCHER 1002 trial 
was a single-arm study that tested the activity of dacomitinib in 
patients that were refractory to one or two lines of chemotherapy 
and erlotinib. On the basis that KRAS mutant cell lines were primar-
ily resistant to first- or second-generation EGFR TKIs, this study 
was enriched with patients with KRAS WT tumors. The trial failed 
to meet its primary end point, as dacomitinib yielded a disappoint-
ing 5.2 and 4.8% of RRs in the overall and adenocarcinoma subsets, 
respectively. Patients with EGFR WT/KRAS WT tumors included 
in this trial had comparable RRs (5%), PFS (8  weeks), and OS 
(26 weeks) to those of the overall study population (25) (Table 1). 
The second phase II trial (ARCHER 1028) compared the activity 
of dacomitinib and erlotinib in molecularly unselected patients pro-
gressing on one or two prior chemotherapy regimens. In this case, 
the trial met its primary endpoint, showing a statistically significant 
increase in PFS (2.86 vs. 1.91 months, HR 0.66, CI 95% 0.47–0.91) 
in favor of dacomitinib in the overall study population. Objective 
responses were also higher in dacomitinib treated patients (17 vs. 
5.3%, p = 0.01). However, no differences in OS were noted (HR 0.80, 
CI 95% 0.56–1.10, p = 0.20) (Table 1). Comparable degree of PFS 
increment to the overall population was observed in EGFR WT 
NSCLCs (HR 0.70, CI 95% 0.47–1.05) and EGFR WT/KRAS 
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WT NSCLCs (HR 0.61, CI 95% 0.37–0.99). Dacomitinib did not 
improve OS compared to erlotinib in patients with EGFR WT 
cancers (24).
This modest clinical activity served as the basis to launch 
two subsequent randomized phase III trials in similar therapeu- 
tic scenarios to their respective phase II trials. Unfortunately, 
both phase III studies were negative. First, in the BR.26 trial, 
whereas dacomitinib statistically significantly improved RRs 
(7 vs. 1%, p = 0.001) and PFS (2.66 vs. 1.38 months, HR 0.66 CI 
95% 0.55–0.79) compared to placebo in patients progressing on 
chemotherapy and EGFR TKIs, it failed to demonstrate improved 
OS (primary end point; HR 1.00) (Table 1). Similarly, no trend 
for a clinically meaningful incremental efficacy was observed in 
patients with EGFR WT tumors or patients with both EGFR and 
KRAS WT NSCLCs compared to the overall patient population 
(27). And finally, Dacomitinib failed to improve the efficacy of 
erlotinib (control arm) in second- or third-line settings (ARCHER 
1009), either in the overall population (Table  1) or in patients 
with EGFR WT tumors. In the latter subgroup, dacomitinib had 
overlapping objective RRs, PFS (1.9 vs. 1.9 months; HR 0.94, CI 
95% 0.79–1.13), and OS (6.8 vs. 7.6 months; HR 1.07, CI 95% 
0.90–1.29) compared to erlotinib. Results were almost identical 
for patients with either KRAS or EGFR WT NSCLCs (26).
Clinical Data in EGFR-Mutant, TKi-Naïve 
NSCLCs
In the particular case of pretreated, TKI-naïve subsets, a pooled 
analysis of the ARCHER 1009 and ARCHER 1028 trials compar-
ing the efficacy of dacomitinib vs. erlotinib showed a comparable 
median PFS (14.6 vs. 9.6 months, respectively; HR 0.71, p = 0.14) 
and OS (26.6 vs. 23.2 months, respectively; HR 0.73, p = 0.26) 
outcomes that somehow favored dacomitinib (28) (Table 2). Both 
ARCHER 1028 and ARCHER 1009 trials showed that on target 
adverse events related to the inhibition of EGFR WT in normal 
tissues were significantly increased with dacomitinib compared 
to erlotinib, mainly skin rash, paronychia, and gastrointestinal 
toxicities (24, 26). These data are in line with the recently pub-
lished LUX-Lung 7 trial, where afatinib significantly delayed PFS 
and the emergence of EGFR TKI resistance, albeit with a higher 
incidence of treatment related adverse events (29).
Clinical Data in EGFR-Mutant,  
TKi-Pretreated NSCLCs
In the context of EGFR TKI acquired resistance, the clinical effi-
cacy of dacomitinib in patients with EGFR-mutant lung cancers 
progressing on first-generation EGFR TKIs that were included 
in these trials was disappointingly low, with an overall RR of 
about 8% (Table 2). No objective responses were reported among 
patients whose tumors harbored the secondary acquired resistance 
EGFR T790M mutation. In general, the PFS and OS data did not 
differ to those of the unselected patient population either (25, 27).
Clinical Data in HER2-Mutant,  
TKi-Naïve NSCLCs
In the largest prospective phase II study conducted to date in 
patients with HER2-mutant or HER2-amplified tumors (n = 30; 
TABLe 2 | Clinical data of dacomitinib in eGFR-mutant NSCLCs.
Study Phase Clinical context No. of patients with  
eGFR-mutant tumors  
(sensitizing mutations)
Response rates (%) PFS OS
A7471017 (30) II Treatment naive 45 76 18.2 months –
Pooled analysis ARCHER 1009  
and ARCHER 1028 (28)
II and III Chemotherapy-pretreated,  
TKI naive
101 67.9 14.6 months 26.6 months
ARCHER 1002 (25) II TKI resistant 24 8 18 weeks 56 weeks
BR.26 (27) III TKI resistant 114 – 3.52 months 7.23 months
PFS, progression-free survival; OS, overall survival; TKI, tyrosine-kinase inhibitor; NSCLCs, non-small cell lung cancers.
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83% had received at least one line of previous chemotherapy), 
dacomitinib showed only modest efficacy, with an objective RR 
of 12%, 3 months of median PFS, and 9 months of median OS. No 
responses were seen in patients with tumors harboring the most 
common HER2 activating mutation (c. 2324_2325ins12) (31). 
Intriguingly, tumors with this genotype did respond to afatinib in 
other series (32). No responses were seen either in patients with 
HER2-amplified cancers (n = 4) (31). More studies are needed 
in order to determine which molecular contextures (i.e., possible 
coexistence with HER2 amplification) and what specific HER2 
genotypes are true predictive targets for the benefit of dacomitinib.
CONCLUSiON AND FUTURe 
PeRSPeCTiveS
Dacomitinib has failed to improve overall outcomes in pretreated 
NSCLC patients. An irreversible pan-HER inhibition is not 
superior to erlotinib in patients with no EGFR-sensitizing muta-
tions and does not prolong OS compared to placebo in heavily 
pretreated patients either. Also, dacomitinib does not overcome 
EGFR T790M-mediated acquired resistance in EGFR-mutant 
NSCLCs at tolerable doses in humans. In non-T790M-mediated 
resistance, in which functional activation of HER pathway or 
acquired HER2 activating mutations have been described in some 
cases (18, 33), no reliable clinical data are available, but a robust 
activity in this clinical setting seems unlikely. With these clinical 
data, together with recent regulatory approvals of third-generation, 
EGFR-mutant selective TKIs (e.g., osimertinib) with potent activ-
ity against the T790M mutation (34), current development of dac-
omitinib is focused to TKI treatment-naïve, molecularly selected 
patients with EGFR-mutant and HER2-mutant lung cancers. In 
a small phase II trial including a total of 45 treatment-naïve 
patients with tumors harboring common EGFR-sensitizing muta-
tions, dacomitinib achieved an overall RR of 75.6% and a median 
PFS of 18.2 months (30).
In this regard, whether second-generation EGFR TKIs in 
TKI-naïve patients are superior to first-generation TKIs in EGFR-
mutant NSCLCs is not fully answered to date. In the LUX-Lung 7 
trial, afatinib significantly increased RRs (70 vs. 56%; p = 0.0083), 
median PFS (11 vs. 10.9  months; HR 0.73, CI 95% 0.57–0.95; 
p  =  0.0195), and median time to treatment failure (13.7 vs. 
11.5 months; HR 0.73, CI 95% 0.58–0.92; p = 0.0073) over gefinitib. 
However, there were no OS differences among treatment arms 
in this phase IIb trial (n = 319). Pre-specified subgroup analysis 
according to mutation type (exon 19 deletions vs. L858R muta-
tions) did no show significant differences in OS either. Overall, 
treatment-related adverse events (mainly skin rash and diarrhea) 
and serious adverse events were more common with afatinib 
(33). Therefore, this trial suggests that the emergence of acquired 
resistance might be delayed with second-generation compared to 
first-generation TKIs, but whether these modest differences are 
clinically relevant for patients is arguable for many physicians. 
The ARCHER 1050 trial (NCT01774721) comparing first-line 
dacomitinb vs. gefitinib has recently completed accrual and will 
hopefully give a definitive answer in this regard, establishing the 
true role of front-line dacomitinib in EGFR-mutant NSCLCs.
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